Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Early Phase 1First-in-human
1(100.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Not yet recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (100.0%)

Trials by Status

terminated133%
not_yet_recruiting133%
completed133%

Recent Activity

0 active trials
Showing 3 of 3
completed

MAC Project, Monitoring of AntiCoagulant Therapies (MAC)

NCT04329390
not_yet_recruitingearly_phase_1

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
terminated

The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)

NCT03977363

Clinical Trials (3)

Showing 3 of 3 trials
NCT04329390

MAC Project, Monitoring of AntiCoagulant Therapies (MAC)

Completed
NCT06615596Early Phase 1

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

Not Yet Recruiting
NCT03977363

The Portuguese Survey on Anticoagulated Patients Register (START-Portugal-Register)

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3